Pharmacologic SubstanceAmino Acid, Peptide, or Protein
nci:P108
p53:264-272 Peptide
nci:P175
717111
nci:P200
Peptide_Vaccine
nci:P204
Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some 'Cytotoxic T-Lymphocyte'Chemical_Or_Drug_Has_Physiologic_Effect some 'T-Cell Activation'Chemical_Or_Drug_Has_Physiologic_Effect some ImmunopotentiationChemical_Or_Drug_Has_Mechanism_Of_Action some 'Antigen Sensitization'
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic peptide derived from the tumor suppressor protein p53 with potential use in cancer immunotherapy. p53:264-272 peptide consists of amino acid residues 264 through 272 of the p53 protein. Vaccination with this agent may induce a cytotoxic host immune response to tumor cells. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:P98
Thu May 24 14:54:19 EDT 2012 - See 'p53_Peptide_Vaccine'